| 产品编号 |
产品名称 |
产品包装 |
产品价格 |
| SF5404-25mg |
R1530 (VEGFR抑制剂) |
25mg |
1574.00元 |
化学信息：
|
化学名
|
5-(2-chlorophenyl)-7-fluoro-8-methoxy-3-methyl-1,2-dihydropyrazolo[3,4-b][1,4]benzodiazepine
|
|
|
简称
|
R1530
|
|
别名
|
UNII-XQJ55R5PPQ, CHEMBL1980391, R1530, C18H14ClFN4O
|
|
中文名
|
N/A
|
|
化学式
|
C18H14ClFN4O
|
|
分子量
|
356.78
|
|
CAS号
|
882531-87-5
|
|
纯度
|
98%
|
|
溶剂/溶解度
|
Water<1mg/ml; DMSO54mg/ml; Ethanol<1mg/ml
|
|
溶液配制
|
5mg加入1.4ml DMSO，或者每3.57mg加入1ml DMSO，配制成10mM溶液。SF5404-10mM用DMSO配制。
|
生物信息：
|
产品描述
|
R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. In addition, this agents exhibits anti-proliferative activity by initiating mitotic arrest and inducing apoptosis.
|
|
信号通路
|
Protein Tyrosine Kinase
|
|
靶点
|
VEGFR
|
PDGFR
|
－
|
－
|
－
|
|
IC50
|
－
|
－
|
－
|
－
|
－
|
|
体外研究
|
In the presence of R1530, polyploid cancer cells underwent apoptosis or became senescent which translated into potent in vitro and in vivo efficacy. Normal proliferating cells were resistant to R1530-induced polyploidy thus supporting the rationale for cancer therapy by induced polyploidy. Mitotic checkpoint kinase BubR1 was found downregulated during R1530-induced exit from mitosis, a likely consequence of PLK4 inhibition. R1530 strongly inhibited human tumor cell proliferation. Growth factor-driven proliferation of endothelial and fibroblast cells was also inhibited.
|
|
体内研究
|
Significant tumor growth inhibition was demonstrated in a lung cancer xenograft model with a range of once daily, weekly and twice-weekly doses of R1530 (3.125-50mg/kg qd, 100mg/kg qw, 100mg/kg biw). Daily doses were most effective in the lung cancer model and also had significant growth inhibitory effects in models of colorectal, prostate, and breast tumors. Tumor regression occurred in all models treated with the maximum tolerated daily dose (50mg/kg). The doses of 25 and 50mg/kg qd resulted in biologically significant increased survival in all tested models. After oral administration in nude mice, R1530 showed good tissue penetration. Exposure was dose dependent up to 100mg/kg with oral administration.
|
|
临床实验
|
A Multiple Ascending Dose Study of R-1530 in Patients With Advanced Solid Tumors. Phase 1.
|
|
特征
|
N/A
|
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
|
酶活性检测实验
|
|
方法
|
N/A
|
|
细胞实验
|
|
细胞系
|
N/A
|
|
浓度
|
N/A
|
|
处理时间
|
N/A
|
|
方法
|
N/A
|
|
动物实验
|
|
动物模型
|
N/A
|
|
配制
|
N/A
|
|
剂量
|
N/A
|
|
给药方式
|
N/A
|
参考文献：
1. Tovar C, et al. Cell Cycle. 2010 Aug 15, 9(16), 3364-75.
2. Kolinsky K, et al. Cancer Chemother Pharmacol. 2011 Dec, 68(6), 1585-94.
包装清单：
|
产品编号
|
产品名称
|
包装
|
|
SF5404-10mM
|
R1530 (VEGFR抑制剂)
|
10mM×0.2ml
|
|
SF5404-5mg
|
R1530 (VEGFR抑制剂)
|
5mg
|
|
SF5404-25mg
|
R1530 (VEGFR抑制剂)
|
25mg
|
|
—
|
说明书
|
1份
|
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：
本产品对人体有刺激性，操作时请小心，并注意适当防护以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。